KR930700143A - Hepatitis B Vaccine - Google Patents

Abstract

No content.

Description

Hepatitis B Vaccine

Since this is an open matter, no full text was included.

1 is a schematic of a portion of a normal HBsAgamino acid sequence pointing to the two loops of the “a” determinant and a glycine residue at position 145.

Figure 2 shows the nucleotide sequence of the clinically isolated variant HBsAg indicating the primer binding site used for PCR and sequencing, and the AGA codon found at position 587-589 where G at position 587 is mutated to A in the normal sequence. Schematic diagram of.

3 is a schematic of S-gene on plasmid pRIT10601 or pRIT13438 showing oligonucleotide binding sites for polymerase chain reaction (PCR).

Claims (13)

A hepatitis B antigen protein or fragment thereof showing the antigenicity of an HBV surface antigen, wherein the glycine contains a modified “a” determinant substituted with another amino acid at position 145 of the HBsAg sequence. The vHBsAg of claim 1, wherein the glycine residue at position 145 is substituted with a more hydrophilic amino acid. The vHBsAg of claim 1, wherein the amino acid at position 145 can be induced by a point mutation in a GGA codon that encodes a glycine at position 145 in normal HBsAg. The vHBsAg of claim 1, wherein the vHBsAg is identical to the HBsAg S-protein except for the altered amino acid residue at position 145. The vHBsAg of claim 1, wherein the modification at position 145 is a substitution of glycine for arginine. The vHBsAg of any one of claims 1-5, wherein the purity is at least 75%. An expression vector comprising a DNA sequence encoding the vHBsAg rate according to any one of claims 1 to 5. A host transformed with the vector of claim 7. Vaccine composition, characterized in that the effective amount of vHBsAg as claimed in claim 6 is mixed with a suitable carrier or adjuvant. A process for preparing vHBsAg according to any one of claims 1 to 6, comprising culturing the host of claim 8 in a suitable culture medium and purifying the resulting vHBsAg to the required degree of purity. Use of vHBsAg according to any one of claims 1 to 6 for the manufacture of a vaccine for protection of human against diseases associated with HBV. In vitro the anti-vHBsAg antibody in a biological medium comprising (a) vHBsAg according to any one of claims 1 to 6, and (b) a means adapted for searching for an antigen-antibody response. Diagnostic Search Kit. An antibody formulation comprising an anti-vHBsAg antibody for use in preventing or treating a B-hepatitis infection in humans. ※ Note: The disclosure is based on the initial application.